Company Overview of Xenikos B.V.
Xenikos B.V. develops toxin-loaded anti-T-cell antibodies as a therapeutic tool for resetting the body’s immune system in T-cell mediated diseases. It identifies and eliminates adult T cells, with a strong preference for the activated ones. Xenikos B.V. was founded in 2009 and is based in Nijmegen, the Netherlands.
Founded in 2009
31 24 300 0100
31 84 741 0735
Key Executives for Xenikos B.V.
Chief Development Officer
Compensation as of Fiscal Year 2017.
Xenikos B.V. Key Developments
Xenikos B.V. Presents at BIO One-on-One Partnering™, Jan-07-2018
Dec 14 17
Xenikos B.V. Presents at BIO One-on-One Partnering™, Jan-07-2018 . Venue: San Francisco, California, United States.
Xenikos B.V. Announces Data from Phase I/II Trial with T-Guard Treatment of Steroid-Resistant Acute GVHD
Dec 11 17
Xenikos B.V. announced that detailed efficacy and safety data from a clinical phase I/II trial with T-Guard for the second-line treatment of steroid-resistant acute graft-versus-host disease (GVHD) were presented at the 59th Annual Meeting of the American Society of Hematology (ASH) in Atlanta, GA. The study enrolled twenty adult patients with a median age of 53, who all had received an allogeneic stem cell transplant for myeloid or lymphoid malignancies and had Grade II-IV steroid-resistant acute GVHD. Patients were treated with T-Guard administered as a four-hour intravenous infusion every 48 hours for a total of four infusions (4 mg/m2 each). The primary efficacy endpoint was defined as overall clinical response (ORR) on day 28. Main secondary endpoints were CR rate at day 28 and 6-month overall survival (OS), as well as safety and tolerability. Treatment with a short course of T-Guard was generally well tolerated with no significant infusion reactions. There was a limited number of potentially T-Guard-related adverse events, which consisted of thrombocytopenia, micro-angiopathy and hypoalbuminemia. The adverse events were manageable and reversible after treatment. The Company is planning to initiate a pivotal multi-center global active-controlled trial, comparing T-Guard with best-available therapy for steroid-resistant acute GVHD in the first half of 2018.
Xenikos Appoints Eric van Hooren as Chief Development Officer
Nov 2 16
Xenikos B.V., announced that it has hired Eric van Hooren as Chief Development Officer. Mr. van Hooren has over 20 years of experience in the pharmaceutical industry, including extensive work in clinical project and clinical trial management. Prior to joining Xenikos, he was Director Clinical Operations at Acerta-Pharma. At Xenikos, Mr. van Hooren will be responsible for preparing and executing the EU/US randomized active-controlled Phase 2 pivotal study of T-Guard in acute graft-versus-host disease (GVHD), as well as exploring new potential indications that might benefit from T-Guard's promise as a therapeutic tool for safely and swiftly resetting the body's immune system in T-cell-mediated diseases. He will take over the responsibilities of Dr. Edna Venneker, who is leaving the company to pursue another opportunity.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries